# Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

> **NCT05255991** · PHASE3 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 597 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** Inhaled Treprostinil
- **DEVICE:** Treprostinil Ultrasonic Nebulizer

## Key facts

- **NCT ID:** NCT05255991
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-04
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 597 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255991, "Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05255991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*